Treatment of neoplasms with viruses
AssigneeWellstat Biologics Corporation
InventorsMichael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
Life of this patent
Estimating the term…
Abstract
The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.
Claims58
A method of infecting a tumor with a volume of ≧300 mm3 in a mammal with a virus comprising systemically administering to said mammal an interferon-sensitive, replication-competent clonal ribonucleic acid (RNA) virus derived from a single infectious virus particle and for which eight individual molecular clones from the population of virions have an identical sequence over 300 contiguous nucleotides, wherein said virus is administered as a first dose and one or more subsequent doses, and wherein the first dose is a desensitizing dose, to thereby infect said tumor, wherein the virus is Newcastle Disease Virus (NDV).
A method of treating a tumor with a volume of ≧300 mm3 in mammal comprising systemically administering to said mammal a therapeutically effective amount of an interferon-sensitive, replication-competent clonal ribonucleic acid (RNA) virus derived from a single infectious virus particle and for which eight individual molecular clones for the population of virions have an identical sequences over 300 contiguous nucleotides, wherein said virus is administered as a first dose and one or more subsequent doses, and wherein the first dose is a desensitizing dose, to thereby treat said tumor, wherein the virus is Newcastle Disease Virus (NDV).
A method of infecting a neoplasm in a mammal with a virus comprising systemically administering an interferon-sensitive, replication-competent clonal ribonucleic acid (RNA) virus derived from a single infectious virus particle and for which eight individual molecular clones from the population of virions have an identical sequence over 300 contiguous nucleotides, wherein said virus is administrated as a first dose and one or more subsequent doses, wherein the first dose is a desensitizing dose, and wherein said one or more subsequent doses are higher than the first dose, to thereby infect said neoplasm, wherein the virus is Newcastle Disease Virus (NDV).
A method of treating a tumor in a mammal comprising systemically administering to said mammal a therapeutically effective amount of an interferon-sensitive, replication-competent clonal ribonucleic acid (RNA) virus derived from a single infectious virus particle and for which eight individual molecular clones from the population of virions have an identical sequence over 300 contiguous nucleotides, wherein said virus is administered as a first dose and one or more subsequent doses, wherein the first dose is a desensitizing dose and wherein said one or more subsequent doses are higher than the first dose, to thereby treat said tumor, wherein the virus is Newcastle Disease Virus (NDV).
A method of infecting a neoplasm in a mammal with a virus comprising systemically administering an interferon-sensitive, replication-competent clonal ribonucleic acid (RNA) virus derived from a single infectious virus particle and for which eight individual molecular clones from the population of virions have an identical sequence over 300 contiguous nucleotides, wherein said virus is administered as a first dose and one or more subsequent doses, wherein the first dose is a desensitizing dose, and wherein said one or more subsequent doses are higher than the first dose, to thereby infect said neoplasm, wherein said virus is selected from the group consisting of the Newcastle disease virus strain MK107 and Newcastle disease virus strain NJRoakin, Sindbis virus, and Vesicular stomatitis virus.
Dependencies are inferred from the claim text.